Electronic eye glasses for treatment of Amblyopia in children.
Employees: 2
Professionals: 2
Overview
OPHTHOCARE LTD.had developed unique electronic eye glasses for
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
treatment of ocular disorders and nerve stimulation applications.
The LCG (Liquid Crystal Glasses) provide a better solution than
the adhesive eye patches used today. The LCG perform the
occlusion process in intervals using an electronic LC shutter
which is incorporated in the optical refractive lens.
The LCG has achieved high compliance in the clinical trials and a
better success rate in the treatment of Amblyopia. The LCG is
comfortable to the child, friendly, simple to use, integrated
into his day to day activities, esthetically acceptable, and
safe. The LCG therapy will provide: higher compliance of the
children, higher efficacy, and a shorter treatment period. This
type of therapy can work either as a primary treatment or as a
method of maintenance after the traditional patching regimen has
achieved best recovery.
LCG are electronically controlled eyeglasses using a Liquid
Crystal technology lens that electronically performs the
occlusion- penalization of the healthy eye.
The LCG incorporates a refractive correction lens mounted when
required (~80% of cases).
The LC lens is controlled by microchip circuitry that switches
the lens of the sound eye from an opaque "ON" position
("occlusion") to that of a transparent "OFF" position according a
preprogrammed modality.
The occlusion of the healthy eye is performed periodically for a
short time of several seconds with 10 -30 seconds rest between
occlusion intervals. This rapid and frequent transition to the
opaque mode is training actively the muscles and neural pathways
while enabling vision maintenance in the healthy eye and
relaxation of the amblyopic one. This type of treatment provides
training in binocular vision fashion.
The treatment modality is easily programmable via PC using
special, user friendly interface screens. The software enables
programming of several modes that change automatically over time
(starting with soft treatment to more aggressive).
Additional features include a special bedside device "Compliance
meter" that performs as a charger and provides indication of
actual wear time, giving feedback to the child, parents and
physicians regarding wearing compliance (actual and prescribed
times).
OPHTHOCARE signed on January 2006 a Joined development Agreement
(JDA) with a large multibillion French company, worldwild leader
in ophthalmic lenses (Essilor) to work together on enhancing the
product in areas of aesthetics, liability and quality.
OPHTHOCARE is in the process o raise additional capital for
production, marketing inventory and ongoing R&D.
